McKesson Corporation $MCK Shares Sold by Chase Investment Counsel Corp

Chase Investment Counsel Corp lowered its holdings in McKesson Corporation (NYSE:MCK) by 38.4% during the third quarter, Holdings Channel reports. The fund owned 6,261 shares of the company’s stock after selling 3,900 shares during the quarter. McKesson makes up 1.4% of Chase Investment Counsel Corp’s holdings, making the stock its 23rd largest holding. Chase Investment Counsel Corp’s holdings in McKesson were worth $4,836,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MCK. Vanguard Group Inc. grew its position in McKesson by 2.0% during the 2nd quarter. Vanguard Group Inc. now owns 12,072,090 shares of the company’s stock worth $8,846,186,000 after purchasing an additional 232,286 shares during the period. Geode Capital Management LLC boosted its stake in shares of McKesson by 4.1% in the second quarter. Geode Capital Management LLC now owns 2,820,724 shares of the company’s stock worth $2,057,065,000 after buying an additional 112,224 shares during the last quarter. Alliancebernstein L.P. grew its holdings in McKesson by 150.4% during the second quarter. Alliancebernstein L.P. now owns 2,268,015 shares of the company’s stock worth $1,661,956,000 after acquiring an additional 1,362,386 shares during the period. Norges Bank acquired a new stake in McKesson during the second quarter worth about $1,346,661,000. Finally, Arrowstreet Capital Limited Partnership raised its position in McKesson by 56.4% during the second quarter. Arrowstreet Capital Limited Partnership now owns 1,236,536 shares of the company’s stock valued at $906,109,000 after acquiring an additional 446,060 shares in the last quarter. 85.07% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

MCK has been the topic of a number of analyst reports. Weiss Ratings cut shares of McKesson from a “buy (a-)” rating to a “buy (b+)” rating in a research note on Thursday, February 5th. Evercore restated an “outperform” rating and set a $1,000.00 price target on shares of McKesson in a research report on Thursday, November 6th. Zacks Research downgraded shares of McKesson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 25th. Robert W. Baird set a $968.00 target price on shares of McKesson in a research note on Wednesday, January 14th. Finally, Wells Fargo & Company lifted their price target on McKesson from $914.00 to $925.00 and gave the company an “equal weight” rating in a research note on Thursday, February 5th. Thirteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, McKesson has a consensus rating of “Moderate Buy” and a consensus target price of $943.50.

McKesson Trading Up 0.0%

NYSE:MCK opened at $947.58 on Tuesday. The company has a market cap of $116.07 billion, a P/E ratio of 27.25, a P/E/G ratio of 1.53 and a beta of 0.40. McKesson Corporation has a twelve month low of $598.58 and a twelve month high of $971.93. The company’s 50-day moving average price is $856.14 and its 200-day moving average price is $798.99.

McKesson (NYSE:MCK) last released its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, beating analysts’ consensus estimates of $9.19 by $0.15. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The company had revenue of $106.16 billion during the quarter, compared to the consensus estimate of $105.98 billion. During the same quarter in the prior year, the firm earned $8.03 EPS. McKesson’s quarterly revenue was up 11.4% on a year-over-year basis. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, analysts expect that McKesson Corporation will post 32.77 earnings per share for the current year.

McKesson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be given a dividend of $0.82 per share. The ex-dividend date is Monday, March 2nd. This represents a $3.28 dividend on an annualized basis and a yield of 0.3%. McKesson’s dividend payout ratio (DPR) is presently 9.43%.

Insider Buying and Selling

In other news, EVP Thomas L. Rodgers sold 276 shares of the business’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $816.18, for a total transaction of $225,265.68. Following the transaction, the executive vice president owned 2,268 shares of the company’s stock, valued at approximately $1,851,096.24. The trade was a 10.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Leann B. Smith sold 190 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $945.00, for a total transaction of $179,550.00. Following the completion of the sale, the executive vice president directly owned 2,989 shares of the company’s stock, valued at $2,824,605. This represents a 5.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 1,143 shares of company stock worth $1,046,070. 0.08% of the stock is currently owned by corporate insiders.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.